+ TCS and q2w + TCS groups, including pruritus, pain, sleep disturbance, symptoms of anxiety and depression, and quality of life (QoL). Treatment groups had similar overall rates of adverse events (qw + TCS, q2w + TCS and placebo + TCS groups: 69Á1%, 72Á0% and 69Á4%, respectively) and serious adverse events (1Á8%, 1Á9% and 1Á9%, respectively). Conjunctivitis was more frequent with dupilumab + TCS; skin infections were more frequent with placebo + TCS. Conclusions Dupilumab + TCS significantly improved signs and symptoms of atopic dermatitis and QoL in adults with a history of inadequate response to/intolerance of CsA, or for whom CsA treatment was medically inadvisable. No new safety signals were identified.
What's already known about this topic?
• Patients with atopic dermatitis that is inadequately controlled with topical therapy have few systemic treatment options.
• Ciclosporin A (CsA) is a systemic immunosuppressant approved for atopic dermatitis in most European countries and Japan, but not all patients respond, and sideeffects limit its use.
• Dupilumab (monoclonal antibody against interleukin-4 receptor-alpha) with/without topical corticosteroids (TCS) is approved in the U.S.A. and the European Union for the treatment of adults with inadequately-controlled moderate-to-severe atopic dermatitis.
What does this study add?
• In this 16-week trial in adults with atopic dermatitis and history of inadequate response or intolerance to CsA, or for whom CsA treatment was medically inadvisable, dupilumab administered weekly or every 2 weeks with concomitant TCS significantly improved signs and symptoms and quality of life, with no new safety signals.
• These data support the use of dupilumab in this difficult-to-treat population.
Atopic dermatitis is a chronic pruritic inflammatory skin disease that features activation of Type 2/T-helper (Th2) immune responses, and an altered skin barrier and skin microbiome. [1] [2] [3] [4] [5] [6] [7] [8] For patients with an inadequate response or intolerance to topical therapies, guidelines recommend systemic immunosuppressants [e.g. ciclosporin A (CsA), methotrexate, azathioprine or mycophenolic acid], although these treatments show variable efficacy/effectiveness and tolerability, and may be complicated by adverse effects and adverse medication interactions both in the short and long term. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Phototherapy is also recommended, but cannot be used as long-term treatment and has risks including burning, skin ageing, adverse medication interactions and skin cancer. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Unlike other systemic immunosuppressants, CsA is approved in many European countries and Japan for severe atopic dermatitis when systemic therapy is required. CsA suppresses Th1, Th2 and Th17/22, affecting both humoral and cellular immune responses. 19, 20 Long-term use (beyond 1 year) of CsA, as may be required in atopic dermatitis, is limited by risk of side-effects, although off-label use beyond 1 year has been reported. 17, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] Side-effects associated with
CsA include hypertension, nephrotoxicity and subjective sideeffects (e.g. headache, paraesthesia in fingers and toes, fatigue). 17, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] Its use is also limited by contraindications because of other medical conditions. Thus, patients with atopic dermatitis who are unresponsive to or who are unable to use topical medications or CsA have few treatment options. Given the chronicity of atopic dermatitis and the need for long-term pharmacological therapy, new treatment options with better benefit-risk profiles are needed. Dupilumab, a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor-alpha, is a targeted agent that selectively inhibits signalling of IL-4 and IL-13, key cytokines of type 2/Th2 inflammation. 40 Dupilumab is approved in the U.S.A. for the treatment of adults with moderate-to-severe atopic dermatitis whose disease is inadequately controlled by topical therapies, or when such treatments are not advisable, and can be used with or without topical corticosteroids (TCS). 41 Dupilumab has also been approved by the European Medicines Agency for use in adults with moderateto-severe atopic dermatitis who are candidates for systemic therapy. 42 In patients with moderate-to-severe atopic dermatitis who had inadequate response to topical medications, dupilumab alone or with TCS significantly improved clinical signs and symptoms of atopic dermatitis. [43] [44] [45] [46] [47] [48] In these studies, adverse events (AEs) that were more frequent with dupilumab included conjunctivitis and injection-site reactions, but there was no increase in infections or serious AEs (SAEs) compared with placebo. [43] [44] [45] [46] [47] In addition, dupilumab is being investigated in other Type 2/Th2 diseases. Positive data have been reported in clinical trials with dupilumab in patients with asthma, [49] [50] [51] chronic rhinosinusitis with nasal polyposis 52 and eosinophilic oesophagitis, 53 providing evidence of a common Type 2/Th2 mechanism underlying these diseases. The present study expands upon previous studies of dupilumab in patients with moderate-to-severe atopic dermatitis by evaluating the efficacy and safety of dupilumab with concomitant TCS in patients with atopic dermatitis and a history of inadequate response or intolerance to CsA, or CsA-na€ ıve patients for whom CsA treatment was medically inadvisable.
Patients and methods

Study design
LIBERTY AD CAF E (ClinicalTrials.gov Identifier: NCT02755649; EudraCT: 2015-002653-35) was a randomized, double-blind, placebo-controlled, parallel-group, phase III clinical study (Fig. 1 ). Patients were enrolled at academic institutions, hospitals and clinics in 10 European countries in which systemic CsA has been approved for atopic dermatitis. Patients were recruited by individual sites, based on reviews of patient databases, referrals and advertising. See Appendix S2 (Supporting Information) for additional details about our methods.
Patients
Main inclusion criteria were: individuals ≥ 18 years of age with chronic atopic dermatitis according to American Academy of Dermatology consensus criteria; 1 where treatment with a potent TCS is indicated; there has been an inadequate response to TCS (as defined by investigator) within the 6 months before screening; a history of (i) prior CsA (Table S1 ; see Supporting Information) and independent ethics committees reviewed and approved the protocol, the informed consent form and patient information. An independent data monitoring committee (IDMC) monitored patient safety.
Study procedures, randomization and treatments
The screening period ran from day À28 to baseline, and included a TCS standardization period, which ran from day À14 to baseline ( Fig. 1) . At baseline, patients were randomized (1 : 1 : 1) to receive 16 weeks of subcutaneous dupilumab 300 mg weekly (qw) or subcutaneous dupilumab 300 mg every 2 weeks (q2w) or placebo, using a central interactive voice-/web-response randomization system, stratified by baseline IGA score (3 or 4) and prior CsA exposure (yes/no). At baseline, patients received a loading dose of 600 mg dupilumab or matching placebo, followed thereafter by subcutaneous dupilumab 300 mg qw or q2w, or placebo. For blinding purposes, patients assigned to dupilumab q2w + TCS received placebo on weeks when dupilumab was not administered. The blinded study drug (dupilumab or placebo) was provided in coded kits with a medication numbering system. Except for the statistician who provided the randomization sequence, the IDMC statistician and IDMC members, the study remained blinded to all individuals until prespecified unblinding. Emergency unblinding was permitted for a medical emergency, an SAE that was unexpected or for which a causal relationship to study drug could not be ruled out, or for any other significant medical event. During Weeks 17-28, patients were followed for safety or could enter an open-label extension study (R668-AD-1225; ClinicalTrials.gov: NCT01949311; EudraCT: 2013-001449-15).
During the initial 2 weeks of the screening period, patients could use TCS at investigator discretion. Starting at day À14, and during the study treatment period, all eligible patients applied medium-potency TCS once daily to active lesion areas, or low-potency TCS on areas of thin skin (e.g. face, neck, intertriginous and genital areas) or where continued treatment with medium-potency TCS was considered unsafe. Patients could stop TCS upon adverse reaction to the TCS. Patients achieving an IGA of 0 by Weeks 4, 8 or 12 could taper TCS to every other day.
After Week 4, patients who continued to have an IGA of 0 for 4 weeks could switch TCS to twice per week; if they did not continue to have an IGA of 0 they would revert to daily dosing. Patients with clear skin continued to apply TCS to lesion-prone areas at intervals of every other day (if prior to day 57) or twice weekly (after day 57), as described above.
During the safety follow-up, patients could remain on TCS at investigator discretion. Patients recorded TCS use in a medication diary; tubes were weighed at each visit through Week 16. Patients were instructed to apply emollients twice daily for the 7 days prior to randomization and throughout the study; stable doses of prescription moisturizers or moisturizers containing additives were permitted if initiated before screening.
Patients could receive rescue medication, including potent or very potent TCS, topical calcineurin inhibitors or systemic medication, if medically necessary (e.g. to control intractable atopic dermatitis symptoms), at investigator discretion. Patients who received rescue medication were considered treatment failures, but continued study visits and assessments; those on topical rescue medication could continue study treatment, whereas those on systemic rescue medication discontinued study treatment (Appendix S2, prohibited concomitant medications; see Supporting Information).
End points
The primary end point was the proportion of patients with ≥ 75% improvement from baseline in EASI score (EASI-75) at Week 16. Secondary end points were the following (all at Week 16, unless otherwise indicated): per cent change from baseline in EASI, SCORing Atopic Dermatitis (SCORAD), weekly average of peak daily pruritus numerical rating scale (NRS) (Weeks 2 and 16) and Global Individual Sign Score (GISS); change from baseline in per cent BSA affected by atopic dermatitis, Dermatology Life Quality Index (DLQI), Patient-Oriented Eczema Measure (POEM) and Hospital Anxiety and Depression Scale (HADS); mean weekly dose of TCS during the treatment period; and proportions of patients with ≥ 50% or ≥ 90% improvement from baseline in EASI score (EASI-50 or EASI-90), EASI-75 (among patients with prior CsA exposure), ≥ 4-point reduction in weekly average of peak daily pruritus NRS score (among patients with baseline pruritus NRS score ≥ 4), ≥ 50% improvement from baseline in SCORAD (SCORAD-50) and both IGA 0 or 1 (clear or almost clear) and a 2-point reduction in IGA from baseline.
Post hoc analyses included: mean change from baseline in EASI, SCORAD and pruritus NRS scores; mean change from baseline in SCORAD visual analogue scale for sleep; and proportions of patients reporting 'no problem' on the pain/discomfort subscale on the generic five-dimension three-level EuroQoL scale (among patients reporting moderate-to-severe pain/discomfort at baseline), reporting 'no days' or '1-2 days' for number of nights that sleep was disturbed in the past week (POEM item 2) (among patients reporting 3-7 nights with missed sleep the previous week at baseline), achieving ≥ 4-point improvement in DLQI score [minimal clinically important difference (MCID)] (among patients with baseline DLQI ≥ 4), 54 achieving ≥ 4-point improvement in POEM score (MCID) (among patients with baseline POEM ≥ 4) 55 and achieving HADS anxiety (HADS-A) and depression (HADS-D) scores < 8 (among patients with HADS-A or HADS-D ≥ 8 at baseline). 56 
Statistical analyses
Approximately 110 patients were planned for each treatment group -approximately 70 with previous exposure to CsA and 40 with no exposure (Appendix S3; see Supporting Information). Target accrual was approximately 330 patients (110 per arm, including 70 with prior CsA exposure and 40 with no prior CsA exposure); this provided 99% power for the primary end point, assuming EASI-75 rates of 60Á1% in the dupilumab arms and 26Á4% in the placebo group, based on results of a 16-week phase IIb study 44 and a 12-week phase IIa study 43 in patients with moderate-to-severe atopic dermatitis, by prior CsA use and CsA-na€ ıve patients.
Significance was set to P = 0Á05, two-sided. To account for multiplicity arising from comparison of each of the dupilumab + TCS dose groups with placebo + TCS, efficacy analyses were carried out in sequential order, following an end point hierarchy for each dupilumab dose regimen (Appendix S3; see Supporting Information). The study was not powered for comparison of the two dupilumab dose regimens. Significance values were considered nominal for post hoc analyses.
For the primary efficacy end point and other binary end points, the Cochran-Mantel-Haenszel test adjusted by randomization strata [disease severity (IGA 3 or 4) and prior CsA use (yes/no)], was used to compare each dupilumab + TCS group with placebo + TCS. Patients were specified as being 'nonresponders' at rescue medication initiation. Continuous end points were analysed using multiple imputation with AN-COVA; data after rescue medication usage was set to missing, and imputed by multiple imputation. For post hoc responder analyses, values after first rescue treatment were set to missing; patients with missing scores at week 16 were considered to be 'nonresponders' (Appendix S3; see Supporting Information).
Safety assessments are reported for the 16-week treatment period, and include AEs, treatment-related AEs, SAEs and AEs leading to discontinuation or death. Efficacy assessments were based on the full-analysis set, which included all randomized patients, based on the treatment allocated as randomized (intention-to-treat). Safety analyses were based on the safety population, which included all randomized patients who received any study drug, based on the treatment received.
Analyses used SAS version 9.2 or above (SAS Institute, Cary, NC, U.S.A.).
Results
Patient disposition and baseline characteristics
Between January and December 2016, 390 patients were screened and 325 randomized to one of three groups: 300 mg dupilumab qw + TCS (n = 110), 300 mg dupilumab q2w + TCS (n = 107) or placebo + TCS (n = 108) ( Fig. S1 and Table S2 ; see Supporting Information).
Baseline characteristics were similar among treatment groups overall (Table 1) , and in subgroups based on prior CsA use (Table S3 ; see Supporting Information). Median atopic dermatitis duration was 30 years. At baseline, the median EASI score was 31Á1-31Á7, 75% of patients reported moderate or severe pain/ discomfort, 59% reported sleep disruption in 3-7 nights over the past week and 65% had previously received CsA. Most patients completed the study treatment (98Á2%, 100% and 95Á4% in the qw + TCS q2w + TCS and placebo + TCS groups, respectively) by data cut-off (5 January 2017); 3 (3%) in the placebo + TCS group withdrew from study treatment because of lack of efficacy, and 2 (2%) each in the placebo + TCS and dupilumab qw + TCS groups withdrew because of AEs.
Efficacy
Primary end point
The proportion of patients achieving EASI-75 at Week 16 was significantly higher in the dupilumab qw + TCS and q2w + TCS groups vs. placebo + TCS (59Á1% and 62Á6% vs. 29Á6%, respectively; P < 0Á001, each dose group vs. placebo + TCS) ( Table 2 , Fig. 2a ).
Secondary end points
Significantly more patients receiving dupilumab + TCS achieved EASI-50 and EASI-90 at Week 16 than placebo + TCS (Table 2 ; Fig. 2b, c) . Among patients with prior exposure to CsA, significantly more receiving dupilumab + TCS achieved EASI-75 vs. placebo + TCS (Table 2 ; Fig. 2d ). Dupilumab + TCS significantly improved EASI and SCORAD scores from baseline to Week 16 vs. placebo + TCS (Table 2 , Fig. 3a, b Fig. 5a, b) . The proportion of patients who achieved HADS-A and HADS-D subscores < 8 (among patients with HADS-A or HADS-D ≥ 8 at baseline) by Week 16 was significantly higher in the dupilumab q2w + TCS group, but not the qw + TCS group, vs. placebo + TCS (Table 2 , Fig. 5c ). Results of sensitivity analyses were similar to the primary analyses (Table S5 ; Figs S2-5, 6b, 7b, 8b; see Supporting Information).
Medication use
The dupilumab + TCS groups used a lower mean weekly dose by weight of TCS vs. placebo + TCS (Table 2) . Fewer patients receiving dupilumab + TCS vs. placebo + TCS used rescue medication ( Table 3 ). The most frequently used rescue medication was potent TCS.
Safety
Similar proportions of patients in the dupilumab qw + TCS, q2w + TCS and placebo + TCS groups reported AEs (Table 4) . Few patients permanently discontinued treatment because of AEs. Two patients in each treatment group experienced SAEs; none were considered related to study treatment. No deaths occurred during the study.
The dupilumab + TCS groups had higher rates of conjunctivitis and injection-site reactions than the placebo + TCS group, whereas the placebo + TCS group had higher rates of nonherpetic skin infections and atopic dermatitis exacerbations (Table 4, Tables S6, S7 ; see Supporting Information). There were no clinically meaningful differences in laboratory values between treatment groups (data not shown). Conjunctivitis [including Medical Dictionary for Regulatory Activities Preferred Terms (MedDRA PTs) conjunctivitis, conjunctivitis allergic, conjunctivitis bacterial, conjunctivitis viral and atopic keratoconjunctivitis] was reported in 16%, 28% and 11% of patients in the dupilumab qw + TCS, q2w + TCS and placebo + TCS groups, respectively; all but one event were mild or moderate (Table S6 ; see Supporting Information). Most conjunctivitis events (89%, 62% and 87%, respectively) were recovered/resolved or recovering/resolving by the end of treatment (Table S6; see Supporting Information) .
Herpes viral infections were reported in 7%, 5% and 6% of patients in the dupilumab qw + TCS, q2w + TCS and placebo + TCS groups, respectively (Table S8 ; see Supporting Information). The more serious forms of herpes viral infections (e.g. eczema herpeticum, ophthalmic herpes simplex and ophthalmic herpes zoster) occurred only in the placebo + TCS group. No localized herpes infections were severe and all but one had recovered/resolved by the end-of-treatment visit.
Discussion
Treatment options are limited for patients with atopic dermatitis who previously failed to respond to CsA or experienced CsA-related AEs, or for whom CsA use is inadvisable because of concomitant medical conditions or risk of drug interactions. This study demonstrates that dupilumab + TCS significantly improves skin lesions, pruritus and other symptoms of atopic dermatitis including pain/discomfort and sleep disruption, symptoms of anxiety and depression and HRQoL in this difficult-to-treat patient population. No new safety signals were identified in this study. Significantly more patients receiving dupilumab + TCS achieved EASI-75 at Week 16 (primary efficacy end point) vs. placebo + TCS. Among patients receiving dupilumab + TCS, 85% achieved a 50% reduction from baseline in EASI at Week 16 -a clinically meaningful response in this patient population with a high baseline burden of disease. Results in the subgroup of patients with prior exposure to CsA were consistent with the overall population. Outcomes for the two dupilumab dose regimens were generally similar. These results are consistent with those of previous studies of dupilumab in patients with moderate-to-severe atopic dermatitis inadequately controlled with topical medications. [43] [44] [45] [46] [47] [48] This study expands upon the previous studies in two principal ways. Firstly, unlike previous studies, the patients in this study were candidates for systemic treatment, and had either not responded to or had experienced intolerance to CsA, or for whom use of CsA treatment was medically inadvisable. Secondly, this study evaluated dupilumab on a background of treatment with TCS and patients could not discontinue TCS, unless for safety reasons, unlike in previous studies of dupilumab with concomitant TCS use, in which TCS could be stopped if lesions cleared. [43] [44] [45] [46] [47] [48] Patients with moderate-to-severe atopic dermatitis who need systemic therapy experience a significant burden of disease. [57] [58] [59] [60] [61] Atopic dermatitis symptoms can profoundly affect sleep, daily functioning, mental/emotional state, concomitant medication use and HRQoL, particularly in patients with untreated or inadequately treated atopic dermatitis. [57] [58] [59] [60] [61] Improvement in patient-reported outcomes was significant in both the dupilumab + TCS treatment groups, except for the proportion of patients who achieved HADS-A and HADS-D scores < 8 (among patients with HADS-A or HADS-D ≥ 8 at baseline), which was significantly greater with dupilumab q2w + TCS, but not qw + TCS; however, both dupilumab + TCS dose regimens showed significant improvement in mean change in HADS score from baseline. Improvement in pruritus was rapid; divergence between dupilumab + TCS and placebo + TCS was significant by Week 2. By significantly improving a wide range of atopic dermatitis symptoms (including pruritus, pain/discomfort and sleep), in addition to aspects of mental health and HRQoL, dupilumab + TCS improved not only skin lesions but also the broader burden associated with moderate-to-severe atopic dermatitis in this patient population, consistent with previous studies. [43] [44] [45] [46] [47] [48] The choice of TCS background therapy as a control was consistent with European guidelines for patients eligible for systemic CsA, 11, 12, 16 and reflects real-world practice. Patients receiving placebo + TCS used significantly more background TCS and rescue medication than the dupilumab + TCS groups, another indicator of better disease control with dupilumab + TCS compared with background TCS alone.
Several factors may help to account for the effect of placebo + TCS treatment on efficacy. Some 'placebo + TCS effect' may appear because of the natural waxing and waning clinical course of atopic dermatitis. In addition, the protocol requirement for patients with an inadequate response to TCS is not the same as no response to TCS. As noted, patients in the placebo group applied TCS and emollients in a continuous manner in a controlled setting under the supervision of a principal investigator. This alone may be responsible for an approximate 10% improvement in the per cent change in EASI score, as can be seen by comparing the Week 16 placebo response in LIBERTY AD CHRONOS (À48Á4%) 47 with the Week 16 response in the monotherapy LIBERTY AD SOLO 1 (À37Á6%) and LIBERTY AD SOLO 2 (À30Á9%) trials. 46 The effect would be expected to be greater in a trial requiring continuous use of TCS (unlike CHRONOS, in which patients could stop TCS if their lesions cleared). This suggests that even patients who were candidates for systemic therapy could still obtain some benefit from continuous treatment with TCS. Nonetheless, in CAF E the significantly greater efficacy of dupilumab + TCS than placebo + TCS demonstrates that dupilumab provides clinically meaningful improvement over any improvement provided by background therapy with TCS in this patient population. Treatment groups had similar overall rates of AEs and SAEs; no new safety signals were identified. Dupilumab + TCS was Data are n (%). TCS, topical corticosteroids; q2w, every 2 weeks; qw, weekly; TCI, topical calcineurin inhibitors. not associated with increased overall risk of infections. Conjunctivitis and injection-site reactions were more frequent with dupilumab + TCS, whereas skin infections and atopic dermatitis exacerbations were more frequent with placebo + TCS, consistent with previous studies of dupilumab in atopic dermatitis. 43, 44, 46, 47 Decreased incidence of nonherpetic skin infections in dupilumab-treated patients in this study, as in previous studies, adds to the body of evidence suggesting that dupilumab may restore skin barrier function. Conjunctivitis rates in this study, especially MedDRA PTs of conjunctivitis and allergic conjunctivitis, were higher in all treatment groups than in previous studies. 44, 46, 47 In addition, more patients in this study reported a history of allergic conjunctivitis at baseline (36Á4%, 41Á1% and 54Á6% in the dupilumab qw + TCS, q2w + TCS and placebo + TCS groups, respectively) compared with previous studies (e.g. LIBERTY AD CHRONOS, 21Á6-28Á2%). 44, 46, 47 This may partly be because of an increased awareness of conjunctivitis following publication of previous studies, in addition to the regional distribution of study sites (most patients were from Germany and Poland), compared with previous studies, which were conducted not only in Europe, but also in countries in North America and the Asia-Pacific. However, most conjunctivitis events were of mild or moderate severity and resolved while patients were still on treatment. No patient withdrew from study treatment because of an AE of conjunctivitis. Interestingly, dupilumab is not associated with increased conjunctivitis rates in studies in other diseases, including asthma [49] [50] [51] and chronic rhinosinusitis with nasal polyposis, 52 suggesting that the increased rates of conjunctivitis in atopic dermatitis studies may reflect a unique interaction between atopic dermatitis-and dupilumab-related mechanisms. Further evaluations of conjunctivitis are ongoing to better characterize the aetiology, clinical features and most effective treatments. As a chronic disease, atopic dermatitis requires long-term treatment options. In the present study, dupilumab + TCS was evaluated for 16 weeks. Safety and efficacy of dupilumab + TCS in the present study are similar to those observed at 52 weeks in a subset of patients in the CHRONOS study (n/N = 126/623) with baseline characteristics similar to the patient population in the present study. 47, 62 Safety of dupilumab beyond 1 year is being evaluated in the open-label extension study. Oral CsA is a broad immunosuppressant prescribed for patients with severe atopic dermatitis whose disease warrants systemic treatment. Although it may be effective in the short term in patients with severe atopic dermatitis, use of CsA is limited because of the risk of several types of side-effects, and the label restricts use to 1 year. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] In addition, cessation of CsA treatment can lead to disease rebound, which is difficult to manage. Concern about these issues has led to reluctance among some physicians to initiate CsA therapy. The data from this 16-week clinical trial show that dupilumab is highly efficacious and well tolerated among patients not adequately controlled with or intolerant to CsA, or for whom CsA is medically inadvisable, giving physicians an important new treatment option. No blood monitoring is required for dupilumab; 41, 42 however, blood monitoring may be required in some regions based on local guidelines. This study had limitations. It was not designed to compare the two dupilumab dose regimens; however, results were similar for both regimens. In addition, the study was not designed to compare CsA-treated and CsA-na€ ıve subgroups. In both subgroups, patients had been considered for CsA treatment, but CsA-na€ ıve patients did not receive CsA because it was considered medically inadvisable (e.g. because of preexisting hypertension or use of statins).
In conclusion, 16 weeks of dupilumab + TCS compared with placebo + TCS significantly improved signs and symptoms of atopic dermatitis and HRQoL, reduced use of concomitant TCS and rescue medications, and had an acceptable safety profile in adults with atopic dermatitis with a history of inadequate response or intolerance to CsA, or for whom CsA was medically inadvisable. These data support the use of dupilumab + TCS as a targeted biological therapy in this difficult-to-treat population.
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